SCHEMBL16287573

SCHEMBL16287573

COC(=O)C1(c2ccc(OC)cc2)CCC(=O)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 1/20 0.48
F10 P00742 1/20 0.46
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 2/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43
TET3 O43151 1/20 0.43
KMT2A Q03164 1/20 0.43
FBXL19 Q6PCT2 1/20 0.43
CXXC5 Q7LFL8 1/20 0.43
TET1 Q8NFU7 1/20 0.43
KDM2B Q8NHM5 1/20 0.43
CXXC4 Q9H2H0 1/20 0.43
KDM2A Q9Y2K7 1/20 0.43
ATM Q13315 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL837139 0.89 ALDH1A1 (0.55) F10ALDH1A1SMN1; SMN2KDM4EMAPT
SCHEMBL11096445 0.86 KMT2A (0.57) KCNA3ALDH1A1SMN1; SMN2KDM4EMAPT
SCHEMBL16897591 0.86 OPRM1 (0.47) KCNA3ALDH1A1SMN1; SMN2KDM4EMAPT
SCHEMBL8179850 0.86 F10 (0.47) KCNA3F10ALDH1A1SMN1; SMN2KDM4E
SCHEMBL8586765 0.85 KDM4E (0.58) ALDH1A1SMN1; SMN2KDM4EMAPTMAPK1
SCHEMBL15348097 0.84 PDE4A (0.39) KCNA3F10ALDH1A1PDE4APDE4B
SCHEMBL11047897 0.84 OPRM1 (0.47) KCNA3F10ALDH1A1SMN1; SMN2MAPT
SCHEMBL8587646 0.84 KDM4E (0.57) ALDH1A1SMN1; SMN2KDM4EMAPTMAPK1
SCHEMBL5765569 0.84 MEN1 (0.50) KCNA3KMT2AL3MBTL1
SCHEMBL4876849 0.82 ADAM17 (0.50) KCNA3ALDH1A1SMN1; SMN2KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2813508-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2018-01-31 EP disclosed
US-9493484-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-11-15 US disclosed
US-20150051197-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-02-19 US disclosed
EP-2813508-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2014-12-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051197-A1 HETEROCYCLIC COMPOUND AND USE THEREOF GRIN1, GRIN2A, GRIN2C KCNA3 1591/4885F10 4246/4885ALDH1A1 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.